Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell CarcinomaBusiness Wire • 03/31/21
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell CarcinomaBusiness Wire • 03/30/21
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UCZacks Investment Research • 03/19/21
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial CarcinomaBusiness Wire • 03/18/21
Exelixis, Inc. (EXEL) Presents at Oppenheimer 31st Annual Healthcare Conference (Transcript)Seeking Alpha • 03/16/21
Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at 2021 Barclays Global Healthcare Conference (Transcript)Seeking Alpha • 03/09/21
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics PipelineBusiness Wire • 03/08/21
Exelixis' (EXEL) CEO Mike Morrissey on Cowen 41st Annual Health Care Conference - TranscriptSeeking Alpha • 03/02/21
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell CarcinomaBusiness Wire • 02/26/21
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in MarchBusiness Wire • 02/25/21
Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid CancerBenzinga • 02/25/21
Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerBusiness Wire • 02/25/21
Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021Business Wire • 02/19/21
Exelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor SettingsBenzinga • 02/16/21
Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney CancerBenzinga • 02/16/21
Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GUBusiness Wire • 02/13/21
Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary TumorsBusiness Wire • 02/12/21
Exelixis' (EXEL) CEO Mike Morrissey on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/11/21